Booster Shot of Hepatitis B Vaccine

AIM Honesty Biopharmaceutical Co., Ltd. is a supplier of Booster Shot of Hepatitis B Vaccine from China. Our products are distributed across 31 provinces and municipalities in China, and we welcome domestic and international buyers and partners to develop long-term and stable cooperation with us.

Who Needs a Hepatitis B Booster Shot?

Most people who receive the three-dose hepatitis B vaccine series as scheduled will not need a booster shot. Under normal circumstances, neither children nor adults require a booster shot to achieve lifelong immunity.

However, some special populations may require a Booster Shot of Hepatitis B Vaccine, and we provide reliable protection for these individuals. These groups include patients undergoing dialysis treatment, adults and children who received the vaccine according to a non-standard schedule, and a small number of recipients who are unable to produce a sufficient antibody response.

Product Features

Our hepatitis B vaccination schedule involves administering one dose at 0, 1, and 6 months, providing lifelong protection against the hepatitis B virus for both children and adults.

As a professional vaccine developer, AIM Vaccine recommends that all individuals from birth to 59 years of age receive the hepatitis B vaccine. For added safety, individuals over 60 years of age with or without risk factors for hepatitis B can also be vaccinated.

The hepatitis B vaccine is safe and effective, and most people who receive the vaccine experience no side effects other than temporary pain and soreness at the injection site.

Product Efficacy

The RECVAX® series of hepatitis B vaccines utilizes patented adjuvant technology. In a research study led by Academician Li Lanjuan, the booster immunization effects of four different hepatitis B vaccines were evaluated in children aged 5 to 15 years.

After receiving the 0-1-6 month booster immunization schedule with 10 μg of RECVAX® (Hansenula polymorpha) vaccine, the anti-HBs seropositivity rate at 1, 5, and 8 years after booster immunization reached 83.4%, which was the highest among the four vaccines tested.